CrossrefInfokarte
Advances in resistance mechanisms and counterstrategies for antibody‑drug conjugates in HER2‑low and HER2‑ultralow breast cancer (Review)
Oncology Reports · 2026-10-20 · 56 (6) · 1-15
DOI: 10.3892/or.2026.9214 ↗Abstract
Kein Abstract verfügbar.
EUVIMED